|drug1722||High Dose of KBP-COVID-19 Wiki||1.00|
|drug1534||FilmArray PCR on respiratory samples Wiki||1.00|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
This is an First In Human (FIH), observer-blinded, randomized, placebo-controlled, parallel group study to evaluate the safety and immunogenicity of KBP-COVID-19 vaccine in healthy CoV-2seronegative adult subjects in 2 age groups, Part A (18-49 years) and Part B (50-70 years).
Description: Occurrence of Adverse EventsMeasure: Solicited Administration site reactions Time: 7 days after vaccination
Description: Occurrence of Adverse EventsMeasure: Solicited systemic events Time: 7 days after vaccination
Description: Safety EndpointsMeasure: Unsolicited Adverse Events and medically attended adverse events Time: 43 days after vaccination
Description: Safety EndpointsMeasure: Serious Adverse Events, Medically Attended Adverse Events and New Onset Chronic Diseae Time: 365 days after vaccination
Description: ImmunogenicityMeasure: Vaccine ELISA and neutralizing antibody titers for each treatment group Time: Baseline, Day 8, 15, 22, 29, 43, 90, 181, 273, 365
Description: ImmunogenicityMeasure: Seroconversion rates Time: Days 8, 15, 22, 29, 43, 90, 181, 273, 365
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports